Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now full pipeline small index

COVID: full-pipeline trial registry

5 of 15 indexed COVID trials are currently recruiting.

Corpus placement: #1,140 of 28,707 conditions by registered trial count.

15 US clinical trials · 5 currently recruiting · #1,140 of 28,707 conditions by registered trial count

COVID: 15 US clinical trials tracked, 5 recruiting.

COVID is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is University of Minnesota, running 3 of these trials.

Enrollment posture brief

Registry condition covid

OPEN 5 | RECR 33% | LATE 2 | EARLY 2 | RANK #1140 | SPON 3

Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)

Advanced Lung Non-Small Cell53.3%COVID (this)33%AIDS26.7%Adult Acute Myeloid Leukemia0%Adult Glioblastoma0%
Open-enrollment share among volume-matched conditions near COVID

COVID lists 5 open slots (33% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for COVID on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. COVID is recruiting below its size-band peers.

    5 of 15 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates COVID research.

    University of Minnesota accounts for 3 of 15 trials (20%). 12 distinct sponsors appear on at least one study for this condition label.

  3. Typical COVID enrolment sits around 461 participants.

    Median target enrolment is 461 among the 15 trials that report a genuine target (sentinel values excluded). 2 of those (13.3%) plan for fewer than 100 participants.

  4. COVID research leans observational.

    6 interventional and 9 observational studies make up this index (40% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 21Phase 32

Open and recent trials

15 total, page 1 of 1

RECRUITING 1,500 participants

Prospective Clinical Evaluation of the BioFire Emerging Coronavirus Panel for the Detection of COVID-19 and Other Coronaviruses

BioFire Defense

NCT07221097

RECRUITING NA 1,000 participants

Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test

Aptitude Medical Systems

NCT06744660

RECRUITING Phase 3 820 participants

Outpatient Treatment With Anti-Coronavirus Immunoglobulin

University of Minnesota

NCT04910269

RECRUITING 800 participants

Long-term Impact of Infection With Novel Coronavirus (COVID-19)

University of California, San Francisco

NCT04362150

RECRUITING 250 participants

A Study to Explore the Role of Gut Flora in COVID-19 Infection

ProgenaBiome

NCT04359836

ACTIVE NOT RECRUITING 7,965 participants

Assessing the Safety of Pregnancy In the CoRonavirus (COVID-19) pandEmic

University of California, San Francisco

NCT04388605

ACTIVE NOT RECRUITING 201 participants

COVID-19 Biorepository

University of Kansas Medical Center

NCT04568148

COMPLETED 22,213 participants

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

University of Utah

NCT04467931

COMPLETED Phase 3 593 participants

Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)

University of Minnesota

NCT04546581

COMPLETED 461 participants

Evaluation of Antibody Tests for COVID-19

Washington University School of Medicine

NCT04360954

COMPLETED 250 participants

Early Short Course Corticosteroids in COVID-19

Henry Ford Health System

NCT04374071

COMPLETED NA 143 participants

HSS Covid-19 Antibody Serology Among Surgeons & Anesthesiologists

Hospital for Special Surgery, New York

NCT04389294

COMPLETED 129 participants

Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS)

University of Minnesota

NCT04339998

COMPLETED Phase 1 72 participants

A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19

Apellis Pharmaceuticals

NCT04402060

COMPLETED Phase 2 48 participants

Convalescent Plasma in the Treatment of COVID 19

Trinity Health Of New England

NCT04343261

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1
Phase 3 2

Named interventions

Most-linked intervention names on COVID records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG) Biological
2 trials
Placebo Other
2 trials
APL-9 Drug
1 trials
Convalescent Plasma Biological
1 trials
Point-of-Care Ultrasonography (POCUS) Diagnostic test
1 trials
ARB Drug
1 trials
ACEI Drug
1 trials
Non-ACEI/ARB Drug
1 trials

US sites by state

Facility locations filed on COVID trials. A trial with sites in several states counts in each.

California 6 trials
Texas 4 trials
New York 3 trials
Michigan 3 trials
Virginia 2 trials
Utah 2 trials
Ohio 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this COVID page

15 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This COVID condition card totals 15 registered trials; most-linked intervention Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG); top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.